Bristol-Myers Squibb (BMY) discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group.The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.Three key data points gauge Bristol-Myers Squibb or any dividend paying firm.The key three are:(1) Price(2) Dividends(3) ...
The latest update for the weekly Commitment of Traders (COT) report was released by the Commodity Futures Trading Commission (CFTC) on Friday for data ending on September 10th.This weekly Extreme Positions report highlights the Most Bullish and Most Bearish Positions for the speculator category. Extreme positioning in these markets can foreshadow strong moves in the underlying market.To signify an extreme position, we use the Strength Index (also known as the COT Index) of each instrument, a common method of measuring COT data. The Strength Index is simply a comparison of current trader positions against the range of positions over the ...
Some BackgroundShares of clinical-stage companies developing treatments based on psychedelic compound-based drugs moved lower in early August after the U.S. Food and Drug Administration (FDA) rejected the use of MDMA for post-traumatic stress disorder (source) as submitted by a private company but noted that they were still supportive of psychedelic development given that psychedelic drugs showed initial promise as potential treatments for mood, anxiety and substance use disorders. Given that encouragement, they saw a 5.9% resurgence last week in the stock prices of the 4 largest companies specializing in psychedelic compound -based clinical-...
Image Source: Pexels More bad news for the property market will continue to weigh on confidence The National Bureau of Statistics published the 70-city housing prices for August, which showed home prices declined at an accelerated pace. New home prices fell by -0.73% MoM, versus a -0.65% MoM dip in July. Secondary market prices fell by -0.95% MoM versus a -0.80% MoM move in July. The drop in new home prices was the steepest monthly decline of this cycle, while the decline in secondary market prices was the steepest since May.Compared to the peak of the cycle, new home prices are now down -8.3% while secondary market prices are down -14.6%....
Image Source: Pixabay The August consumer price index report showed that U.S. inflation slowed to 2.5% Polling markets suggest that the race for the White House remains extremely tight Exports surged in China while inflation stayed soft On the latest edition of Market Week in Review, Director and Senior Investment Strategist Alex Cousley and Senior Internal Communications Analyst McKenna Painter discussed the August U.S. inflation report and its potential market implications. They also chatted about the upcoming U.S. presidential election and unpacked the latest trade and inflation numbers from China.Video Length: 00:04:39 U.S. inflation con...
Stay ahead in the market with our comprehensive Elliott Wave Analysis for Nasdaq Tech Stocks, including the SP500 index and top performers like Amazon (AMZN), Microsoft (MSFT), Meta Platforms (META), and Nvidia (NVDA). Currently, these leading tech stocks are exhibiting strong ranging patterns within Wave V of an impulse wave (1 of 3), positioning them as prime candidates for lucrative long trades once the next setup emerges.Key Insights:Market Conditions: The SP500 and Nasdaq are navigating through Wave V of an Elliott Wave cycle, indicating a potential peak in Wave 1 and a subsequent decline into Wave 2. This shift sets the stage for strate...
Image Source: PixabayGold bugs everywhere, rejoice!Yes, a desire fulfilled is like eating from a fruitful tree.And now, it bares the fruit…Sudden movements for gold prices.Bloomberg reports:Gold Hits Successive Record Highs Ahead of Expected Fed Rate Cut “Bullion climbed as much as 1% to $2,583.45 an ounce on Friday, putting it on track for a weekly gain of more than 3%. Gold has surged by more than a quarter this year, supported by the Fed’s path to monetary easing. Central-bank buying and strong haven demand due to conflicts in the Middle East and Ukraine have helped the advance, while interest from retail investors is also pick...
MARKETSStocks soared again on Friday, capping off a stellar week as investors reveled in anticipation of the Federal Reserve’s expected rate cuts this week. The market is buzzing with excitement as the drumbeat grows louder for a sizable drop in interest rates. With momentum building, the Fed’s next move could spark even more optimism, pushing the bull run even higher.This week’s Fed meeting is setting up to be one of the most eagerly awaited in recent memory—and not because of any grand reveal, but because, for once, nobody knows what’s coming. Typically, by now, investors have made their bets, donned their poker faces, and...
Here are the latest charts and statistics for the Commitment of Traders (COT) data published by the Commodities Futures Trading Commission (CFTC).The latest Commitment of Traders (COT) data is updated through Tuesday September 10th and shows a quick view of how large market participants (for-profit speculators and for-profit speculators) were positioned in the futures markets. All currency positions are in direct relation to the US dollar where, for example, a bet for the euro is a bet that the euro will rise versus the dollar while a bet against the euro will be a bet that the euro will decline versus the dollar.Weekly Speculator Cha...
Image Source: UnsplashAn IntroductionThe AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 which should result in as many as 50 novel therapies being brought to market by then and generate annual sales in excess of $50B.The AI-focused Drug Discovery Stocks PortfolioThe 6 AI-focused clinical-stage drug discovery stocks currently trading on Canadian or American stock exchanges are highlighted below, in descending order, for last week (w/e Sept. 13th), the previous week (Sept. 6th) and in August, along with a description of their areas of focus, their market capitalizations, their product pipeline, the...